Workup for Secondary Hypertension
Screen for secondary hypertension when clinical suspicion is present based on specific high-risk features, starting with basic screening tests (history, physical exam, serum sodium, potassium, eGFR, TSH, urinalysis), then pursue targeted investigations based on clinical clues rather than blanket testing all patients with hypertension. 1
When to Screen: High-Risk Clinical Features
The 2025 AHA/ACC guidelines provide clear triggers for screening 1:
Mandatory Screening Situations
- Resistant hypertension (BP >140/90 mmHg on 3+ medications including a diuretic at optimal doses)
- Early-onset hypertension (<30 years old, especially without typical risk factors like obesity or family history)
- Sudden deterioration in previously controlled BP
- Stage 2 hypertension (may be considered for screening)
- Hypertensive urgency or emergency
Specific Clinical Clues Warranting Screening
- Spontaneous or diuretic-induced hypokalemia
- Obstructive sleep apnea (snoring, daytime sleepiness, neck circumference >40 cm)
- Incidentally discovered adrenal mass
- Family history of early-onset hypertension
- Stroke at young age (<40 years)
- Target organ damage disproportionate to hypertension duration/severity
Critical pitfall: Before pursuing secondary hypertension workup in resistant hypertension, first exclude pseudoresistance (poor BP measurement technique, white coat effect, medication nonadherence, suboptimal drug choices) and substance-induced hypertension 2. Approximately 50% of "resistant" hypertension is actually pseudoresistance 2.
Basic Screening Tests (First-Line for All Suspected Cases)
The 2020 ISH guidelines specify the initial workup 2:
Laboratory Tests
- Serum sodium and potassium (hypokalemia suggests primary aldosteronism)
- Serum creatinine and eGFR (renal parenchymal disease)
- TSH (thyroid disorders)
- Fasting glucose and lipid profile (if available)
Urinalysis
- Dipstick urinalysis (proteinuria/hematuria suggests renal disease)
- Urine albumin-to-creatinine ratio (if dipstick positive)
Physical Examination Clues
- Radio-femoral delay (coarctation of aorta)
- Abdominal/femoral bruits (renovascular disease)
- Enlarged kidneys (polycystic kidney disease)
- Cushingoid features (striae, central obesity, moon facies)
- Neck circumference >40 cm (obstructive sleep apnea)
12-Lead ECG
- Detects left ventricular hypertrophy, atrial fibrillation
Targeted Testing Based on Clinical Suspicion
Primary Aldosteronism (Most Common Endocrine Cause)
Screen ALL patients with resistant hypertension regardless of potassium level 1. The 2025 AHA/ACC guidelines emphasize this is a Class 1 recommendation.
Screening test: Aldosterone-to-renin ratio (ARR)
- Ideally performed before starting interfering antihypertensives (ACE inhibitors, ARBs, diuretics, beta-blockers)
- If already on interfering drugs that cannot be stopped, interpret ARR with caution or seek specialist guidance 3
Confirmatory testing (if ARR positive):
- Intravenous saline suppression test
- Adrenal CT imaging
- Adrenal vein sampling (for lateralization before surgery)
Renovascular Hypertension
Clinical clues: Flash pulmonary edema, abdominal bruits, asymmetric kidney size, acute kidney injury with ACE inhibitor/ARB initiation
Imaging options 2:
- Renal artery duplex ultrasound (first-line, non-invasive)
- CT angiography or MR angiography (depending on renal function)
- Avoid contrast in patients with eGFR <30 mL/min/1.73m²
Pheochromocytoma/Paraganglioma
Clinical clues: Episodic sweating, palpitations, severe headaches, paroxysmal hypertension
Screening test: Plasma free metanephrines or 24-hour urinary metanephrines
Imaging: Abdominal/pelvic CT or MRI if biochemical testing positive
Cushing Syndrome
Clinical clues: Central obesity, purple striae, proximal muscle weakness, easy bruising
Screening tests 2:
- Late-night salivary cortisol
- 24-hour urinary free cortisol
- Dexamethasone suppression test
Imaging: Abdominal or pituitary imaging based on test results
Obstructive Sleep Apnea
Clinical clues: Snoring, witnessed apneas, daytime sleepiness, neck circumference >40 cm, obesity
Testing 2:
- Home sleep apnea testing (level 3 sleep study)
- Overnight polysomnography (gold standard)
Renal Parenchymal Disease
Detected by basic screening: Elevated creatinine, reduced eGFR, proteinuria, hematuria
Further workup: Kidney ultrasound, urine albumin-to-creatinine ratio
Drug/Substance-Induced Hypertension
Review all medications and substances 1:
- NSAIDs, decongestants, oral contraceptives
- Corticosteroids, immunosuppressants (cyclosporine, tacrolimus)
- Stimulants, cocaine, amphetamines
- Herbal supplements (licorice, ephedra)
- Excessive alcohol intake
Algorithmic Approach
- Identify high-risk features → Proceed with screening
- Perform basic screening tests (electrolytes, creatinine, TSH, urinalysis, ECG)
- Review medications/substances → Stop offending agents
- Pursue targeted testing based on clinical clues from history/exam/basic labs
- Refer to specialist if positive screening test for confirmatory testing and treatment 1
Specialist Referral
Refer to hypertension specialist or appropriate subspecialist when 1, 2:
- Positive screening test requiring confirmatory testing
- Complex diagnostic workup needed (e.g., adrenal vein sampling)
- Resistant hypertension despite optimal medical therapy
- Consideration of interventional procedures (renal denervation, surgical adrenalectomy)
Key Pitfalls to Avoid
- Don't screen everyone: Secondary hypertension affects only 5-25% of hypertensive patients 1, 2. Screen selectively based on clinical features.
- Don't forget pseudoresistance: Verify proper BP measurement technique and medication adherence before extensive workup 2.
- Don't miss medication review: Drug-induced hypertension is common and reversible 1.
- Don't check ARR on interfering medications without understanding limitations: ACE inhibitors, ARBs, diuretics, and beta-blockers affect the test 3.
- Don't assume normal potassium excludes primary aldosteronism: Most patients with primary aldosteronism are normokalemic 1.